silevertinib
BDTX-1535 Small Molecule Target: EGFR, EGFRvIII
Black Diamond Therapeutics
Most recent annual filing: 2026-03-16
- Silevertinib FDA feedback4Q 2026Silevertinib FDA feedback, 4Q 2026, major
- Silevertinib Ph2 readout4Q 2026Silevertinib Ph2 readout, 4Q 2026, material
- BH-30643 BlossomHill FDA feedback4Q 2026BH-30643 BlossomHill FDA feedback, 4Q 2026, notable
- Silevertinib Ph2 start4Q 2026Silevertinib Ph2 start, 4Q 2026, routine
- Silevertinib EP opposition deadlineDec 11, 2026Silevertinib EP opposition deadline, Dec 11, 2026, routine
- Black Diamond corporate China decisionDec 18, 2026Black Diamond corporate China decision, Dec 18, 2026, material
- Silevertinib GBM Ph2 interim1H 2028Silevertinib GBM Ph2 interim, 1H 2028, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Technology platforms
MAP · Revelio Therapeutics
Mutation-Allostery-Pharmacology (MAP) drug discovery engine used to identify and develop MasterKey therapies targeting families of oncogenic mutations in cancer; also licensed to Revelio Therapeutics for large molecule therapeutics discovery
MAP
Mutation Allostery Pharmacology (MAP) drug discovery engine — identifies oncogenic mutations across genes, confirms oncogenicity via cell and tumor models, and guides pharmacologic inhibition of mutant proteins while sparing wild-type; used to discover MasterKey inhibitors for genetically defined cancers including NSCLC and GBM
Biotech Distilled coverage (1)
- 2026-10-08 Black Diamond Therapeutics (BDTX) - Scientific Deep Dive for Silevertinib and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.